589 related articles for article (PubMed ID: 31220163)
1. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
[TBL] [Abstract][Full Text] [Related]
3. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
6. The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Uemura S; Iwashita T; Ichikawa H; Iwasa Y; Mita N; Shiraki M; Shimizu M
Br J Nutr; 2021 May; 125(10):1140-1147. PubMed ID: 32883372
[TBL] [Abstract][Full Text] [Related]
7. Limited performance of subjective global assessment compared to computed tomography-determined sarcopenia in predicting adverse clinical outcomes in patients with cirrhosis.
Moctezuma-Velazquez C; Ebadi M; Bhanji RA; Stirnimann G; Tandon P; Montano-Loza AJ
Clin Nutr; 2019 Dec; 38(6):2696-2703. PubMed ID: 30545661
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment.
Sheean PM; Peterson SJ; Gomez Perez S; Troy KL; Patel A; Sclamberg JS; Ajanaku FC; Braunschweig CA
JPEN J Parenter Enteral Nutr; 2014 Sep; 38(7):873-9. PubMed ID: 23980135
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Subjective Global Assessment (SGA) in advanced colorectal cancer.
Gupta D; Lammersfeld CA; Vashi PG; Burrows J; Lis CG; Grutsch JF
Eur J Clin Nutr; 2005 Jan; 59(1):35-40. PubMed ID: 15252422
[TBL] [Abstract][Full Text] [Related]
10. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
11. Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Payette E; Sarker S; Chalchal H
Can J Rural Med; 2017; 22(4):148-152. PubMed ID: 28925914
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer.
Miyamoto Y; Baba Y; Sakamoto Y; Ohuchi M; Tokunaga R; Kurashige J; Hiyoshi Y; Iwagami S; Yoshida N; Yoshida M; Watanabe M; Baba H
Ann Surg Oncol; 2015 Aug; 22(8):2663-8. PubMed ID: 25564158
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Sarcopenia in Patients with Colorectal Cancer.
Souza BU; Souza NCS; Martucci RB; Rodrigues VD; Pinho NB; Gonzalez MC; Avesani CM
Nutr Cancer; 2018; 70(2):176-183. PubMed ID: 29351494
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
17. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
[TBL] [Abstract][Full Text] [Related]
18. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
19. Agreement between PG-SGA category and fat-free mass in colorectal cancer patients.
Ræder H; Henriksen C; Bøhn SK; O de Fey Vilbo AR; Henriksen HB; Kværner AS; Rolid K; Paur I; Smeland S; Blomhoff R
Clin Nutr ESPEN; 2018 Oct; 27():24-31. PubMed ID: 30144889
[TBL] [Abstract][Full Text] [Related]
20. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Kurita Y; Kobayashi N; Tokuhisa M; Goto A; Kubota K; Endo I; Nakajima A; Ichikawa Y
Pancreatology; 2019 Jan; 19(1):127-135. PubMed ID: 30473464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]